| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 14,405.2 | 13,349.1 | 11,850.4 | 9,359.3 |
yoy growth (%) | 7.91 | 12.64 | 26.61 | -3.7 |
Raw materials | -5,045.9 | -4,123 | -3,573.8 | -2,631 |
As % of sales | 35.02 | 30.88 | 30.15 | 28.11 |
Employee costs | -2,434.6 | -2,270.1 | -2,030.2 | -1,843 |
As % of sales | 16.9 | 17 | 17.13 | 19.69 |
Other costs | -4,330.6 | -3,819.2 | -3,376.8 | -3,555.4 |
As % of sales (Other Cost) | 30.06 | 28.61 | 28.49 | 37.98 |
Operating profit | 2,594.1 | 3,136.8 | 2,869.6 | 1,329.9 |
OPM | 18 | 23.49 | 24.21 | 14.2 |
Depreciation | -814.3 | -835 | -789.2 | -774.1 |
Interest expense | -38 | -46.7 | -47.8 | -62.8 |
Other income | 482 | 801.1 | 743.2 | 204 |
Profit before tax | 2,223.8 | 3,056.2 | 2,775.8 | 696.99 |
Taxes | -600.6 | -869.8 | 161.9 | -130.1 |
Tax rate | -27 | -28.46 | 5.83 | -18.66 |
Minorities and other | 0 | 0 | 0 | 0 |
Adj. profit | 1,623.2 | 2,186.4 | 2,937.7 | 566.89 |
Exceptional items | 0 | 0 | 0 | 0 |
Net profit | 1,623.2 | 2,186.4 | 2,937.7 | 566.9 |
yoy growth (%) | -25.75 | -25.57 | 418.2 | -59.04 |
NPM | 11.26 | 16.37 | 24.78 | 6.05 |
Here are some of the stocks that may see significant price movement today: Dr Reddy’s Laboratories, RITES, Canara Bank, etc.
Dr Reddy's already signed a license and commercialisation deal for Toripalimab with Shanghai Junshi Biosciences Co. Ltd in 2023.
Dr Reddy’s Laboratories shares has gained a total of 5.62% in the last one year, and 2.45% since the beginning of the year.
Here are some of the stocks that may see significant price movement today: UPL, Tata Power, JSW Steel, Dr Reddy’s, etc.
EBITDA for the quarter increased 5% year-on-year to ₹2,280 Crore between July and September 2024, while margins improved modestly to 28.4%.
Here are some of the stocks that may see significant price movement today: Dr Reddy’s, Hindustan Zinc, Titan Company, etc.
Here are some of the stocks that may see significant price movement today: Mazagon Dock Shipbuilders, Krsnaa Diagnostics, Dr Reddy's, etc.
The experiment also had a favourable safety profile, with no serious adverse effects such as Cytokine Release Syndrome (CRS) or neurotoxicity reported.
The agreement also includes a provision for Dr. Reddy’s to manufacture and commercialize Lenacapavir for HIV prevention (PrEP) in the same 120 countries, pending approval.
Here are some of the stocks that may see significant price movement today: Welspun Enterprises, IDFC First Bank, Dr Reddy’s Laboratories, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
